Related Experiment Video
Updated: Oct 13, 2025

Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter
Published on: June 16, 2022
Ginsenoside Rg1 attenuates mechanical stress-induced cardiac injury via calcium sensing receptor-related pathway
Mei-Li Lu1, Jing Wang2, Yang Sun1
1The Key Laboratory of Cardiovascular and Cerebrovascular Drug Research of Liaoning Province, Jinzhou Medical University, Jinzhou, China.
Background:
Ginsenoside Rg1 (Rg1) has been well documented to be effective against various cardiovascular disease. The aim of this study is to evaluate the effect of Rg1 on mechanical stress-induced cardiac injury and its possible mechanism with a focus on the calcium sensing receptor (CaSR) signaling pathway.
Methods:
Mechanical stress was implemented on rats through abdominal aortic constriction (AAC) procedure and on cardiomyocytes and cardiac fibroblasts by mechanical stretching with Bioflex Collagen I plates. The effects of Rg1 on cell hypertrophy, fibrosis, cardiac function, [Ca2+]i, and the expression of CaSR and calcineurin (CaN) were assayed both on rat and cellular level.
Results:
Rg1 alleviated cardiac hypertrophy and fibrosis, and improved cardiac decompensation induced by AAC in rat myocardial tissue and cultured cardiomyocytes and cardiac fibroblasts. Importantly, Rg1 treatment inhibited CaSR expression and increase of [Ca2+]i, which similar to the CaSR inhibitor NPS2143. In addition, Rg1 treatment inhibited CaN and TGF-β1 pathways activation. Mechanistic analysis showed that the CaSR agonist GdCl3 could not further increase the [Ca2+]i and CaN pathway related protein expression induced by mechanical stretching in cultured cardiomyocytes. CsA, an inhibitor of CaN, inhibited cardiac hypertrophy, cardiac fibrosis, [Ca2+]i and CaN signaling but had no effect on CaSR expression.
Conclusion:
The activation of CaN pathway and the increase of [Ca2+]i mediated by CaSR are involved in cardiac hypertrophy and fibrosis, that may be the target of cardioprotection of Rg1 against myocardial injury.
Insights
Ginsenoside Rg1 protects against mechanical stress-induced cardiac injury by inhibiting the calcium sensing receptor (CaSR) and calcineurin (CaN) pathways, reducing hypertrophy and fibrosis.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Pharmacology
Background:
- Ginsenoside Rg1 (Rg1) demonstrates efficacy in various cardiovascular diseases.
- Mechanical stress is a known contributor to cardiac injury.
Purpose of the Study:
- To evaluate Rg1's effect on mechanical stress-induced cardiac injury.
- To investigate the role of the calcium sensing receptor (CaSR) signaling pathway in Rg1's cardioprotective mechanism.
Main Methods:
- Mechanical stress induced via abdominal aortic constriction (AAC) in rats and mechanical stretching of cardiomyocytes and cardiac fibroblasts.
- Assessed Rg1's impact on cardiac hypertrophy, fibrosis, function, intracellular calcium ([Ca2+]i), CaSR, and calcineurin (CaN) expression.
Main Results:
- Rg1 alleviated cardiac hypertrophy, fibrosis, and decompensation in vivo and in vitro.
- Rg1 inhibited CaSR expression and [Ca2+]i increase, similar to CaSR inhibitor NPS2143.
- Rg1 inhibited CaN and TGF-β1 pathway activation, while CaN inhibition affected hypertrophy and fibrosis but not CaSR expression.
Conclusions:
- CaSR-mediated CaN pathway activation and increased [Ca2+]i contribute to cardiac hypertrophy and fibrosis.
- These pathways represent potential targets for Rg1's cardioprotection against myocardial injury.
More Related Videos
Related Concept Videos
G-Protein Gated Ion Channels
Sensory...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antihypertensive Drugs: Action of Calcium Channel Blockers
GPCRs Regulate Adenylyl Cylase Activity
Heart Failure Drugs: Inotropic Agents

